NRD
CPRX

Nebula Research & Development’s Catalyst Pharmaceutical CPRX Stock Holding History

Nebula Research & Development’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,418
Closed -$443K – 204
2025
Q2 		$443K Buy
20,418
+4,534
+29% +$107K 0.04% 671
2025
Q1 		$385K Buy
+15,884
New +$358K 0.04% 691
2024
Q2 		– Sell
-10,703
Closed -$171K – 838
2024
Q1 		$171K Buy
+10,703
New +$161K 0.04% 660

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Nebula Research & Development's CPRX Position: Q3 2025 in Review

Nebula Research & Development sold out of Catalyst Pharmaceutical (CPRX) in Q3 2025, closing a stake of 20,418 shares — an estimated $443K sold.

Nebula Research & Development first reported a position in CPRX in Q1 2024 and held it in 3 quarters. The position peaked at $443K in Q2 2025. 360 funds tracked by Wall St. Rank hold CPRX as of Q3 2025.

  • Nebula Research & Development reported no remaining Catalyst Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 20,418 Catalyst Pharmaceutical shares in Q3 2025, an estimated $443K.
  • Nebula Research & Development first reported a position in Catalyst Pharmaceutical in Q1 2024 and held it in 3 quarters.
  • Nebula Research & Development's Catalyst Pharmaceutical position peaked at $443K in Q2 2025.
  • 360 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.